bedrock

Reimagining Oncology Research with Bedrock: A Decade of Innovation in Collaboration with Merck

Over the past ten years, in close collaboration with Merck’s pharmacometrics and oncology teams, we’ve developed Bedrock.
A groundbreaking data visualization platform designed to transform how cancer research data is understood, explored, and shared across disciplines. Traditionally, cancer datasets are siloed and dense, often requiring specialized knowledge to interpret. Bedrock breaks down these barriers by making complex patient and clinical trial data visually accessible and functionally interactive.

At its core, Bedrock integrates real-world evidence, clinical trial outputs, pharmacokinetic/pharmacodynamic (PK/PD) models, and patient-reported outcomes into a unified interface. Scientists can explore tumor response trajectories, treatment timelines, biomarker changes, and safety profiles with clarity and flexibility—drilling down to individual patient journeys or zooming out to cohort-wide trends. Physicians can more easily translate statistical outcomes into patient-facing narratives, while patients gain agency by visualizing how their treatment paths compare with others in similar clinical scenarios.

‍What makes Bedrock truly unique is its cross-functional utility. Whether you're a modeling scientist, clinician, regulatory reviewer, or patient advocate, the system fosters a shared language through visual storytelling. Its layered interactivity supports hypothesis testing, sensitivity analyses, and scenario exploration—enabling faster iteration during trial design and more robust dialogue during regulatory review.

By moving beyond static plots and spreadsheets, Bedrock empowers users to uncover new insights, avoid misinterpretations, and collaborate more effectively across domains.  

Below are two demo videos and a whitepaper presented by a Merck scientist at industry events, offering a closer look at how Bedrock is redefining the future of oncology data analysis.